SP-8356, a (15)-(-)-Verbenone Derivative, Inhibits the Growth and Motility of Liver Cancer Cells by Regulating NF-kappa B and ERK Signaling
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dong Hwi | - |
dc.contributor.author | Yong, Hyo Jeong | - |
dc.contributor.author | Mander, Sunam | - |
dc.contributor.author | Huong Thi Nguyen | - |
dc.contributor.author | Lan Phuong Nguyen | - |
dc.contributor.author | Park, Hee-Kyung | - |
dc.contributor.author | Cha, Hyo Kyeong | - |
dc.contributor.author | Kim, Won-Ki | - |
dc.contributor.author | Hwang, Jong-Ik | - |
dc.date.accessioned | 2021-11-20T14:40:17Z | - |
dc.date.available | 2021-11-20T14:40:17Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1976-9148 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128123 | - |
dc.description.abstract | Liver cancer is a common tumor and currently the second leading cause of cancer-related mortality globally. Liver cancer is highly related to inflammation as more than 90% of liver cancer arises in the context of hepatic inflammation, such as hepatitis B virus and hepatitis C virus infection. Despite significant improvements in the therapeutic modalities for liver cancer, patient prognosis is not satisfactory due to the limited efficacy of current drug therapies in anti-metastatic activity. Therefore, developing new effective anti-cancer agents with anti-metastatic activity is important for the treatment of liver cancer. In this study, SP-8356, a verbenone derivative with anti-inflammatory activity, was investigated for its effect on the growth and migration of liver cancer cells. Our findings demonstrated that SP-8356 inhibits the proliferation of liver cancer cells by inducing apoptosis and suppressing the mobility and invasion ability of liver cancer cells. Functional studies revealed that SP-8356 inhibits the mitogen-activated protein kinase and nuclear factor-kappa B signaling pathways, which are related to cell proliferation and metastasis, resulting in the downregulation of metastasis-related genes. Moreover, using an orthotopic liver cancer model, tumor growth was significantly decreased following treatment with SP-8356. Thus, this study suggests that SP-8356 may be a potential agent for the treatment of liver cancer with multimodal regulation. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC APPLIED PHARMACOLOGY | - |
dc.subject | HEPATOCELLULAR-CARCINOMA | - |
dc.subject | MESENCHYMAL TRANSITION | - |
dc.subject | CLINICAL-FEATURES | - |
dc.subject | INFLAMMATION | - |
dc.subject | METASTASIS | - |
dc.subject | STATISTICS | - |
dc.subject | SORAFENIB | - |
dc.subject | PROGNOSIS | - |
dc.subject | MODEL | - |
dc.title | SP-8356, a (15)-(-)-Verbenone Derivative, Inhibits the Growth and Motility of Liver Cancer Cells by Regulating NF-kappa B and ERK Signaling | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Won-Ki | - |
dc.contributor.affiliatedAuthor | Hwang, Jong-Ik | - |
dc.identifier.doi | 10.4062/biomolther.2020.200 | - |
dc.identifier.scopusid | 2-s2.0-85106477718 | - |
dc.identifier.wosid | 000652473600011 | - |
dc.identifier.bibliographicCitation | BIOMOLECULES & THERAPEUTICS, v.29, no.2, pp.331 - 341 | - |
dc.relation.isPartOf | BIOMOLECULES & THERAPEUTICS | - |
dc.citation.title | BIOMOLECULES & THERAPEUTICS | - |
dc.citation.volume | 29 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 331 | - |
dc.citation.endPage | 341 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002708656 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | MESENCHYMAL TRANSITION | - |
dc.subject.keywordPlus | CLINICAL-FEATURES | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordPlus | METASTASIS | - |
dc.subject.keywordPlus | STATISTICS | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordAuthor | SP-8356 | - |
dc.subject.keywordAuthor | Liver cancer | - |
dc.subject.keywordAuthor | Proliferation | - |
dc.subject.keywordAuthor | Motility | - |
dc.subject.keywordAuthor | ERK | - |
dc.subject.keywordAuthor | NF-kappa B | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.